Recurrent Esophageal Carcinoma
6 clinical trials · Condition
◉ Watch Recurrent Esophageal Carcinoma
| Record | Firm | Date |
|---|---|---|
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery (NCT03008278) | National Cancer Institute (NCI) | 2018-02-06 |
| Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer (NCT03196232) | George Albert Fisher | 2017-09-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (NCT01142388) | National Cancer Institute (NCI) | 2010-09-21 |
Track Recurrent Esophageal Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.